**Author details**

Ilaria Maccora<sup>1</sup> \*, Matteo Della Monica<sup>2</sup> , Giovanna Traficante<sup>2</sup> , Gianpaolo De Filippo<sup>3</sup> and Stefano Stagi<sup>1</sup>

\*Address all correspondence to: ilamaccora@gmail.com

1 Department of Health Sciences, University of Florence, Anna Meyer Children's University Hospital, Florence, Italy

2 Genetics and Molecular Medicine Unit, Anna Meyer Children's University Hospital, Florence, Italy

3 AP-HP, CHU Bicêtre, Service de Médiciine des Adolescents, Le Kremlin-Bicêtre, Paris, France

## **References**


[19] Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry CJ, Siguero JP, Digilio MC, Zampino G, Dallapiccola B, Bar-Sagi D, Gelb BD. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nature Genetics. 2007;**39**:75-79. DOI: 10.1038/ng1939

[6] Moreau D, Waldie KE. Developmental learning disorders: From generic interventions to individualized remediation. Frontiers in Psychology. 2016;**6**:2053. DOI: 10.3389/

[7] Davis S, Laroche S. Mitogen-activated protein kinase/extracellular regulated kinase signalling and memory stabilization: A review. Genes, Brain and Behavior. 2006;**5**:61-72.

[8] Samuels IS, Saitta SC, Landreth GE. MAP'ing CNS development and cognition: An ERK

[9] Atkins CM, Selcher JC, Petraitis JJ, Trzaskos JM, Sweatt JD. The MAPK cascade is required for mammalian associative learning. Nature Neuroscience. 1998;**1**:602-609.

[10] Schalock RL, Luckasson R. A systematic approach to subgroup classification in intellectual disability. Intellectual and Developmental Disabilities. 2015;**53**:358-366. DOI:

[11] Tassé MJ, Luckasson R, Nygren M. AAIDD proposed recommendations for ICD-11 and the condition previously known as mental retardation. Intellectual and Developmental

[12] Aoki Y, Niihori T, Inoue S, Matsubara Y. Recent advances in RASopathies. Journal of

[13] Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y. The RAS/MAPK syndromes: Novel roles of the RAS pathway in human genetic disorders. Human Mutation. 2008;**29**:992-

[14] Tidyman WE, Rauen KA. The RASopathies: Developmental syndromes of Ras/MAPK pathway dysregulation. Current Opinion in Genetics & Development. 2009;**19**:230-236.

[15] Bezniakow N, Gos M, Obersztyn E. The RASopathies as an example of RAS/MAPK pathway disturbances—Clinical presentation and molecular pathogenesis of selected

[16] Rauen KA. The RASopathies. Annual Review of Genomics and Human Genetics.

[17] Korf B, Ahmadian R, Allanson J, Aoki Y, Bakker A, Wright EB, Denger B, Elgersma Y, Gelb BD, Gripp KW, Kerr B, Kontaridis M, Lazaro C, Linardic C, Lozano R, MacRae CA, Messiaen L, Mulero-Navarro S, Neel B, Plotkin S, Rauen KA, Roberts A, Silva AJ, Sittampalam SG, Zhang C, Schoyer L. The third international meeting on genetic disorders in the RAS/MAPK pathway: Towards a therapeutic approach. American Journal of

[18] Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan

Medical Genetics. Part A. 2015;**167A**:1741-1746. DOI: 10.1002/ajmg.a.37089

syndrome. Nature Genetics. 2001;**29**:465-468. DOI: 10.1038/ng772

Disabilities. 2013;**51**:127-131. DOI: 10.1352/1934-9556-51.2.127

Human Genetics. 2016;**61**:33-39. DOI: 10.1038/jhg.2015.114

syndromes. Developmental Period Medicine. 2014;**18**:285-296

2013;**14**:355-369. DOI: 10.1146/annurev-genom-091212-153523

some process. Neuron. 2009;**61**:160-167. DOI: 10.1016/j.neuron.2009.01.001

fpsyg.2015.02053

38 Learning Disabilities - An International Perspective

DOI: 10.1038/2836

10.1352/1934-9556-53.5.358

1006. DOI: 10.1002/humu.20748

DOI: 10.1016/j.gde.2009.04.001

DOI: 10.1111/j.1601-183X.2006.00230.x


[34] Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature. 1993;**366**:643- 654. DOI: 10.1038/366643a0

[27] Pasmant E, Sabbagh A, Hanna N, Masliah-Planchon J, Jolly E, Goussard P, Ballerini P, Cartault F, Barbarot S, Landman-Parker J, Soufir N, Parfait B, Vidaud M, Wolkenstein P, Vidaud D, France RN. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. Journal of Medical Genetics. 2009;**46**:425-430. DOI: 10.1136/

[28] Sarkozy A, Carta C, Moretti S, Zampino G, Digilio MC, Pantaleoni F, Scioletti AP, Esposito G, Cordeddu V, Lepri F, Petrangeli V, Dentici ML, Mancini GM, Selicorni A, Rossi C, Mazzanti L, Marino B, Ferrero GB, Silengo MC, Memo L, Stanzial F, Faravelli F, Stuppia L, Puxeddu E, Gelb BD, Dallapiccola B, Tartaglia M. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: Molecular diversity and associated phenotypic spectrum. Human Mutation. 2009;**30**:695-702. DOI: 10.1002/

[29] Cirstea IC, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D, Roberts AE, Lepri F, Merbitz-Zahradnik T, König R, Kratz CP, Pantaleoni F, Dentici ML, Joshi VA, Kucherlapati RS, Mazzanti L, Mundlos S, Patton MA, Silengo MC, Rossi C, Zampino G, Digilio C, Stuppia L, Seemanova E, Pennacchio LA, Gelb BD, Dallapiccola B, Wittinghofer A, Ahmadian MR, Tartaglia M, Zenker M. A restricted spectrum of NRAS mutations causes Noonan

[30] Flex E, Jaiswal M, Pantaleoni F, Martinelli S, Strullu M, Fansa EK, Caye A, De Luca A, Lepri F, Dvorsky R, Pannone L, Paolacci S, Zhang SC, Fodale V, Bocchinfuso G, Rossi C, Burkitt-Wright EM, Farrotti A, Stellacci E, Cecchetti S, Ferese R, Bottero L, Castro S, Fenneteau O, Brethon B, Sanchez M, Roberts AE, Yntema HG, Van Der Burgt I, Cianci P, Bondeson ML, Cristina Digilio M, Zampino G, Kerr B, Aoki Y, Loh ML, Palleschi A, Di Schiavi E, Carè A, Selicorni A, Dallapiccola B, Cirstea IC, Stella L, Zenker M, Gelb BD, Cavé H, Ahmadian MR, Tartaglia M. Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. Human

[31] Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP. Germline KRAS mutations cause Noonan syn-

[32] Martinelli S, De Luca A, Stellacci E, Rossi C, Checquolo S, Lepri F, Caputo V, Silvano M, Buscherini F, Consoli F, Ferrara G, Digilio MC, Cavaliere ML, van Hagen JM, Zampino G, van der Burgt I, Ferrero GB, Mazzanti L, Screpanti I, Yntema HG, Nillesen WM, Savarirayan R, Zenker M, Dallapiccola B, Gelb BD, Tartaglia M. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndromelike phenotype. American Journal of Human Genetics. 2010;**87**:250-257. doi: 10.1016/j.

[33] Oishi K, Zhang H, Gault WJ, Wang CJ, Tan CC, Kim IK, Ying H, Rahman T, Pica N, Tartaglia M, Mlodzik M, Gelb BD. Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development.

Human Molecular Genetics. 2009;**18**:193-201. DOI: 10.1093/hmg/ddn336

syndrome. Nature Genetics. 2010;**42**:27-29. DOI: 10.1038/ng.497

Molecular Genetics. 2014;**23**:4315-4327. DOI: 10.1093/hmg/ddu148

drome. Nature Genetics. 2006;**38**:331-336. DOI: 10.1038/ng1748

jmg.2008.065243

40 Learning Disabilities - An International Perspective

humu.20955

ajhg.2010.06.015


as a paradigm for translational research. American Journal of Medical Genetics. Part A. 2012;**158A**:2225-2232. DOI: 10.1002/ajmg.a.35535

[60] Hyman SL, Shores A, North KN. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 2005;**65**:1037-1044. DOI: 10.1212/01. wnl.0000179303.72345.ce

[48] Costa RM, Federov NB, Kogan JH, Murphy GG, Stern J, Ohno M, Kucherlapati R, Jacks T, Silva AJ. Mechanism for the learning deficits in a mouse model of neurofibromatosis

[49] San Martín A, Pagani MR. Understanding intellectual disability through RASopathies. Journal of Physiology, Paris. 2014;**108**:232-239. DOI: 10.1016/j.jphysparis.2014.05.003 [50] Costa RM, Silva AJ. Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1. Journal of Child Neurology. 2002;**17**:622-626. DOI:

[51] Mainberger F, Langer S, Mall V, Jung NH. Impaired synaptic plasticity in RASopathies: A mini-review. Journal of Neural Transmission (Vienna). 2016;**123**:1133-1138. DOI:

[52] Darcy MJ, Jin SX, Feig LA. R-Ras contributes to LTP and contextual discrimination.

[53] Cui Y, Costa RM, Murphy GG, Elgersma Y, Zhu Y, Gutmann DH, Parada LF, Mody I, Silva AJ. Neurofibromin regulation of ERK signaling modulates GABA release and

[54] Mainberger F, Jung NH, Zenker M, Wahlländer U, Freudenberg L, Langer S, Berweck S, Winkler T, Straube A, Heinen F, Granström S, Mautner VF, Lidzba K, Mall V. Lovastatin improves impaired synaptic plasticity and phasic alertness in patients with Neurofibromatosis type 1. BMC Neurology. 2013;**13**:131. DOI: 10.1186/1471-2377-13-131

[55] Mainberger F, Zenker M, Jung NH, Delvendahl I, Brandt A, Freudenberg L, Heinen F, Mall V. Impaired motor cortex plasticity in patients with Noonan syndrome. Clinical

[56] Dileone M, Profice P, Pilato F, Alfieri P, Cesarini L, Mercuri E, Leoni C, Tartaglia M, Di Iorio R, Zampino G, Di Lazzaro V. Enhanced human brain associative plasticity in Costello syndrome. Journal of Physiology. 2010;**588**:3445-3456. DOI: 10.1113/

[57] Rauen KA, Huson SM, Burkitt-Wright E, Evans DG, Farschtschi S, Ferner RE, Gutmann DH, Hanemann CO, Kerr B, Legius E, Parada LF, Patton M, Peltonen J, Ratner N, Riccardi VM, van der Vaart T, Vikkula M, Viskochil DH, Zenker M, Upadhyaya M. Recent developments in neurofibromatoses and RASopathies: Management, diagnosis and current and future therapeutic avenues. American Journal of Medical Genetics. Part

[58] Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis

[59] Acosta MT, Bearden CE, Castellanos FX, Cutting L, Elgersma Y, Gioia G, Gutmann DH, Lee YS, Legius E, Muenke M, North K, Parada LF, Ratner N, Hunter-Schaedle K, Silva AJ. The Learning Disabilities Network (LeaDNet): Using neurofibromatosis type 1 (NF1)

type 1 revisited. Pediatrics. 2009;**123**:124-133. DOI: 10.1542/peds.2007-3204

Neurophysiology. 2013;**124**:2439-2444. DOI: 10.1016/j.clinph.2013.04.343

Neuroscience. 2014;**277**:334-342. DOI: 10.1016/j.neuroscience.2014.07.010

learning. Cell. 2008;**135**:549-560. DOI: 10.1016/j.cell.2008.09.060

type 1. Nature. 2002;**415**:526-530. DOI: 10.1038/nature711

10.1177/088307380201700813

42 Learning Disabilities - An International Perspective

10.1007/s00702-016-1609-3

jphysiol.2010.191072

A. 2015;**167A**:1-10. DOI: 10.1002/ajmg.a.36793


required for synaptic plasticity and hippocampus dependent learning. The Journal of Neuroscience. 2008;**28**:14443-14449. DOI: 10.1523/JNEUROSCI.4698-08.2008


**Chapter 3**

**Provisional chapter**
